Ajmaline blocks INa and IKr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters

The class Ia anti-arrhythmic drug ajmaline is used clinically to unmask latent type I ECG in Brugada syndrome (BrS) patients, although its mode of action is poorly characterised. Our aims were to identify ajmaline's mode of action in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Duncan C. Miller, Stephen C. Harmer, Ariel Poliandri, Muriel Nobles, Elizabeth C. Edwards, James S. Ware, Tyson V. Sharp, Tristan R. McKay, Leo Dunkel, Pier D. Lambiase, Andrew Tinker
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2017-12-01
coleção:	Stem Cell Research
Assuntos:	Brugada syndrome hiPSC-cardiomyocytes Ajmaline INa IKr Activation-recovery interval
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1873506117302337
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!